Latest Therapeutics Pipeline News

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.